Crispr Therapeutics remains highly volatile, disconnected from near-term fundamentals, yet I see long-term value far above current levels. CRSP's business progress is slow, with pipeline milestones ...
Newly discovered weapons of bacterial self-defense take different approaches to achieving the same goal: preventing a virus from spreading through the bacterial population. Every living creature on ...
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases. Last February ...
Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable. The funding has enabled CRISPR co-inventor Jennifer Doudna, Ph.D., and baby KJ scientist ...
A headshot shows Jennifer Doudna in front of a gold background. Jennifer Doudna, a cofounder of Aurora Therapeutics, speaks during an interview in 2017 after being awarded the Japan Prize. Credit: AP ...
From diagnostics to CRISPR and policy reform, explore how science and society are working together to combat the rising threat of antibiotic resistance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results